Plain-English translation of NCT06901466 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing two different approaches to blood thinner treatment after a minimally invasive heart valve repair procedure called TEER. You would either take rivaroxaban alone, or rivaroxaban combined with a second blood thinner called clopidogrel for the first three months. The goal is to figure out which approach works best to prevent blood clots while keeping you safe.
Many people who need this heart valve repair also have an irregular heartbeat that requires long-term blood thinning medication. Right now, doctors don't have clear guidelines on the best way to combine blood thinners after this procedure, so treatment varies widely. This trial will provide evidence to help doctors make better, more consistent decisions.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to one of two treatment groups. You will take either one blood thinner medication daily, or the same medication plus a second blood thinner for three months, then continue the first medication alone for at least a year total. You'll have regular follow-up visits and blood tests to monitor how well the treatment is working and watch for any side effects.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
China